DuPont Decomposition

Why does SUNPHARMA earn its ROE?

Breaking down Return on Equity into profitability, efficiency, and leverage.

ROE = Net Margin × Asset Turnover × Equity Multiplier

13.7% = 19.7% × 0.54 × 1.30

Latest: FY2026

Profitability

Net Margin

19.7%

8.5% →19.7%

How much profit per ₹ of revenue

Efficiency

Asset Turnover

0.54x

0.55x →0.54x

Revenue per ₹ of assets

Leverage

Equity Multiplier

1.30x

1.45x →1.30x

Assets funded by equity vs debt

Trend Analysis

ROE improved by 6.9 pp over 5 years. Driven by net margin improving (8.5% → 19.7%).

Historical Decomposition

Last 5 years

YearRevenuePATNet MarginAsset TOLeverageROE
FY20220Cr0Cr8.5%0.551.456.8%
FY20230Cr0Cr19.6%0.541.4415.1%
FY20240Cr0Cr20.1%0.561.3415.0%
FY20250Cr0Cr21.0%0.571.2815.1%
FY20260Cr0Cr19.7%0.541.3013.7%

How to read DuPont

  • Rising ROE from margin = pricing power, operational improvement (good)
  • Rising ROE from turnover = better asset utilization (good)
  • Rising ROE from leverage = more debt, amplified risk (caution)
  • Falling ROE across all three = structural deterioration (red flag)

See DCF fair value for SUNPHARMA

Combine financial quality with intrinsic value.

See Fair Value →

DuPont decomposition from audited annual financials. Factual analysis, not investment advice.

SUNPHARMA DuPont Analysis — ROE 13.7% | YieldIQ